Bizwatch
After a low, shares in Shell may be a bargain
Is It Time to Buy Shell?
Eight months after disclosing that it had massively overstated its proven oil reserves, Royal Dutch/Shell continues to be roiled by a barrage of bad news. Britain's Financial Services Authority and the U.S. Securities and Exchange Commission are still investigating the company, even after announcements last week that they are fining Shell a combined $150 million for "unprecedented misconduct," in the words of the FSA. And Nigeria's Senate passed a resolution calling on the company to pay $1.5 billion for environmental and health hazards it allegedly caused in the Niger Delta.
But with Shell stock at about $7.30 a share in London , or just over 11 times its estimated earnings this year, and other Big Oil stocks such as BP and Exxon Mobil trading closer to 14 times earnings, that suggests: buy. "We can't help but think there is now limited downside risk," said Merrill Lynch analyst Mark Iannotti, while
|
|||||
Losing Ground Control
Ah, summertime, when the livin' is easy and Europe's airlines enjoy a holiday boom right? Not exactly. Alitalia CEO Giancarlo Cimoli last week warned that the state-owned carrier faced collapse within 20 days unless unions agree to cost cuts and layoffs. But downsizing has consequences: British Airways (BA), which has chopped 13,000 jobs since 9/11, last week grounded more than 100 flights at its Heathrow hub.
The main reason: staff shortages. Did BA fumble its math? The carrier blames twice the normal rate of workers quitting the firm earlier in the year, with recruiting delays not helping. Unions disagree: BA "didn't just cut the flab," railed Ed Blisset of the GMB. "It cut into the bone as well." But with quieter winter months approaching, "shareholders would probably prefer [BA] run on edge this time of year," counters one airline analyst. Even CEO Rod Eddington lent a hand at Heathrow late last week a great way to spend a summer holiday. By Adam Smith
The Spitzer Treatment
Britain's GlaxoSmithKline (GSK) reached a $2.5 million settlement with New York Attorney General Eliot Spitzer over allegations that it withheld information about the safety of antidepressant Paxil. GSK also agreed to publish online the results of all its clinical trials since December 2000. Spitzer sued the firm in June, claiming it failed to release data suggesting Paxil could increase suicidal tendencies in children.
| The Bottom Line | |||
| This is an economy with no spare capacity |
|||
| TREVOR WILLIAMS, chief economist at Lloyds TSB, warning that Britain's second-quarter GDP growth of 3.7% year-on-year, its fastest in almost four years, could stoke inflation | |||
Most Popular »
- Nevada Ghosts: Rare Photos From an A-Bomb Test
- E.T. Turns 30: 10 Things You Didn't Know About Our Favorite Extra-Terrestrial
- Before and After D-Day: Rare Color Photos
- A Diamond Jubilee
- 15-Year-Old Creates Test for Pancreatic Cancer
- Marilyn Monroe: Early Unpublished Photos
- Etan Patz: After 33 Years, an Arrest in the Disappearance of the 'Milk-Carton Boy'
- 10 Dangerous Products You Might Have in Your Home
- Vintage Vegas: Rare Photos of a Desert Boomtown
- Why People Stick with Cancer Screening, Even When It Causes Harm
- Researchers Probe the Potential Health Benefits of Palm Oil
- A Visit with Turkey's Controversial Religious Movement
- Feeding the Planet Without Destroying It
- Bubble on the Potomac
- Falcon's Liftoff: How a Private Firm Could Change Space Exploration
- The Fatal Flight of the Superjet 100: Why Did It Slam Into a Mountain?
- Learning That Works
- The Man Who Remade Motherhood
- Bibi's Choice
- Seoul: 10 Things to Do




